1. Sustainability‐Driven Accelerated Shear‐Mediated Immunoassay for Amyotrophic Lateral Sclerosis Detection
- Author
-
Luo, Xuan, Heydari, Amir, Renfrey, Danielle, Gardner, Zoe, He, Shan, Tang, Youhong, Weiss, Gregory A, Rogers, Mary‐Louise, and Raston, Colin L
- Subjects
Analytical Chemistry ,Chemical Sciences ,Rare Diseases ,Brain Disorders ,Neurosciences ,ALS ,Neurodegenerative ,4.1 Discovery and preclinical testing of markers and technologies ,Amyotrophic Lateral Sclerosis ,Humans ,Immunoassay ,Limit of Detection ,Biomarkers ,Portable Vortex Fluidic Device ,P-VFD ,immunoassay ,biomarker ,Other Chemical Sciences ,Chemical Engineering ,General Chemistry ,Organic Chemistry ,Macromolecular and materials chemistry ,Organic chemistry ,Chemical engineering - Abstract
Healthcare facilities produce millions of tons of waste annually, with a significant portion consisting of diagnostic plasticware. Here, we introduce a new detection platform that completely replaces traditional assay plates with a piece of membrane, offering a much greener and more sustainable alternative. The membrane, integrated within the portable vortex fluidic device (P-VFD), enables rapid detection of a clinically relevant protein biomarker, urinary p75ECD. This biomarker is utilized to evaluate the prognosis, disease severity, and progression of amyotrophic lateral sclerosis (ALS). This assay has a limit-of-detection (LOD) of 4.03 pg, which is comparable to the plate-based assay (2.24 pg) and has been optimised through a full factorial design of experiments (DOE) and response surface methodology (RSM). P-VFD has great potential in quantifying p75ECD in human biofluids and can significantly reduce the assay time to 5 min compared to the current plate-based p75ECD ELISA assay (3 days), with at least a 4.4-fold reduction in the usage of the detection antibody.
- Published
- 2024